Beth Faiman

1.6k total citations
93 papers, 1.1k citations indexed

About

Beth Faiman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Beth Faiman has authored 93 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Hematology, 50 papers in Oncology and 41 papers in Molecular Biology. Recurrent topics in Beth Faiman's work include Multiple Myeloma Research and Treatments (67 papers), Protein Degradation and Inhibitors (23 papers) and Cancer Treatment and Pharmacology (22 papers). Beth Faiman is often cited by papers focused on Multiple Myeloma Research and Treatments (67 papers), Protein Degradation and Inhibitors (23 papers) and Cancer Treatment and Pharmacology (22 papers). Beth Faiman collaborates with scholars based in United States, India and Australia. Beth Faiman's co-authors include Joseph D Tariman, Rachid Baz, Gordan Srkalović, Mary Ann Karam, Mohamad A. Hussein, Janice Reed, Jerome B. Zeldis, Steven Andrèsen, Jason Valent and Christy Samaras and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Beth Faiman

87 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth Faiman United States 17 775 536 480 184 106 93 1.1k
Michael R. Grunwald United States 20 810 1.0× 503 0.9× 234 0.5× 387 2.1× 93 0.9× 90 1.5k
Theodore T. Suh United States 14 386 0.5× 165 0.3× 116 0.2× 87 0.5× 28 0.3× 23 1.0k
Bart Heeg United States 19 370 0.5× 303 0.6× 273 0.6× 53 0.3× 11 0.1× 102 1.1k
Robert F. Sidonio United States 22 1.7k 2.1× 196 0.4× 76 0.2× 453 2.5× 84 0.8× 129 2.1k
Raphael Fraser United States 16 308 0.4× 103 0.2× 94 0.2× 243 1.3× 42 0.4× 42 707
Somedeb Ball United States 15 160 0.2× 145 0.3× 290 0.6× 114 0.6× 46 0.4× 99 802
Roger Woodruff Australia 19 586 0.8× 198 0.4× 273 0.6× 289 1.6× 20 0.2× 52 1.3k
Ahmad Naim United States 15 322 0.4× 215 0.4× 99 0.2× 390 2.1× 11 0.1× 45 781
Nina Salooja United Kingdom 14 318 0.4× 92 0.2× 157 0.3× 66 0.4× 71 0.7× 28 868
Gerald L. Logue United States 22 438 0.6× 127 0.2× 124 0.3× 237 1.3× 9 0.1× 53 1.1k

Countries citing papers authored by Beth Faiman

Since Specialization
Citations

This map shows the geographic impact of Beth Faiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Faiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Faiman more than expected).

Fields of papers citing papers by Beth Faiman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Faiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Faiman. The network helps show where Beth Faiman may publish in the future.

Co-authorship network of co-authors of Beth Faiman

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Faiman. A scholar is included among the top collaborators of Beth Faiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Faiman. Beth Faiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dima, Danai, Fauzia Ullah, Beth Faiman, et al.. (2025). Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center. Hematological Oncology. 43(3). e70082–e70082.
2.
Raza, Shahzad, Christy Samaras, Beth Faiman, et al.. (2024). Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia. Blood. 144(Supplement 1). 7092–7092. 1 indexed citations
3.
Banerjee, Rahul, et al.. (2024). Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer Journal. 14(1). 149–149. 7 indexed citations
4.
Dima, Danai, Al‐Ola Abdallah, James A. Davis, et al.. (2024). Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy. Blood Cancer Journal. 14(1). 90–90. 11 indexed citations
5.
Xu, Xuan, Shahzad Raza, Jim E. Riviere, et al.. (2023). Identification of genes encoding targets associated with adverse events in multiple myeloma.. Journal of Clinical Oncology. 41(16_suppl). 1556–1556. 2 indexed citations
6.
Faiman, Beth, et al.. (2023). Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review. Journal of Clinical Medicine. 12(17). 5539–5539. 11 indexed citations
7.
Faiman, Beth, et al.. (2023). Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology. Journal of the Advanced Practitioner in Oncology. 14(3). 223–226. 1 indexed citations
8.
Richards, Tiffany, et al.. (2022). A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 13(5). 31–43. 3 indexed citations
9.
Brigle, Kevin E., et al.. (2022). A Focus on Newly Diagnosed Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 13(5). 7–14. 1 indexed citations
10.
Covut, Fahrettin, Sanchit Chawla, Christy Samaras, et al.. (2021). Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. British Journal of Haematology. 193(6). 1213–1219. 25 indexed citations
11.
Faiman, Beth & Joseph D Tariman. (2019). Shared Decision Making: Improving Patient Outcomes by Understanding the Benefits of and Barriers to Effective Communication. Clinical journal of oncology nursing. 23(5). 540–542. 70 indexed citations
12.
Faiman, Beth, et al.. (2018). Multiple Myeloma Education: Results From the ACE Program’s Digital, Serial Learning Approach. Clinical journal of oncology nursing. 22(5). E120–E126. 1 indexed citations
13.
Faiman, Beth, et al.. (2017). Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma. Clinical journal of oncology nursing. 21(5). 19–36. 4 indexed citations
14.
Sidana, Surbhi, Mayur Narkhede, Paul Elson, et al.. (2017). Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 12(3). e0172996–e0172996. 18 indexed citations
15.
Kurtin, Sandra & Beth Faiman. (2013). The Changing Landscape of Multiple Myeloma. Clinical journal of oncology nursing. 17(s6). 7–11. 7 indexed citations
16.
Lilleby, K, et al.. (2013). Autologous Hematopoietic Stem Cell Transplantation for Patients With Multiple Myeloma. Clinical journal of oncology nursing. 17(s6). 13–24. 9 indexed citations
17.
Faiman, Beth, et al.. (2013). Clinical Updates in Blood and Marrow Transplantation in Multiple Myeloma. Clinical journal of oncology nursing. 17(s6). 33–41. 5 indexed citations
18.
Faiman, Beth, et al.. (2012). Survey of Experiences of an E-Mentorship Program: Part II. Clinical journal of oncology nursing. 16(1). 50–54. 6 indexed citations
19.
Faiman, Beth. (2007). Clinical Updates and Nursing Considerations for Patients With Multiple Myeloma. Clinical journal of oncology nursing. 11(6). 831–840. 10 indexed citations
20.
Baz, Rachid, Esteban Walker, Mohamed A. Karam, et al.. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 17(12). 1766–1771. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael R. Grunwald Breakdown of academic impact, for papers by Theodore T. Suh Breakdown of academic impact, for papers by Bart Heeg Breakdown of academic impact, for papers by Robert F. Sidonio Breakdown of academic impact, for papers by Raphael Fraser Breakdown of academic impact, for papers by Somedeb Ball Breakdown of academic impact, for papers by Roger Woodruff Breakdown of academic impact, for papers by Ahmad Naim Breakdown of academic impact, for papers by Nina Salooja Breakdown of academic impact, for papers by Gerald L. Logue
Rankless by CCL
2026